RESEARCH ATLAS
← Compound index
COMPOUND RECORD / STABINORM

StabinormСтабинорм

Recovery
Source linked

What the studies found

The linked records do not yet support a study-level summary for this preparation. Original publications require verification; additional research may exist.

01 / OVERVIEW

About Stabinorm

Names in this research collection

Stabilorm · RU2390348C1

A Russian patent describes a mixture of ginseng, Eleutherococcus, leuzea, nettle and St John’s wort, with rodent stress experiments.

Research background

A Russian patent describes a mixture of ginseng, Eleutherococcus, leuzea, nettle and St John’s wort, with rodent stress experiments.

Russian ME/CFS and fatigue research ↗

Compound class
Five-extract botanical formulation
Research collection
Russian ME/CFS and fatigue research · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Rodent data in the patent examples.

Study methods

Rodent comparisons with water controls in the original patent.

Independent replication

The linked patent contains the available experimental findings.

Source access

The linked study records provide the original articles or trial registrations.

Safety evidence

Available adverse-event findings and follow-up periods appear in the study notes.

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original experiments cited in the reviews, patents or bibliography remain unavailable.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2010 · RU2390348C1 · Stabinorm botanical mixture for a claimed fatigue useFormulation · Open-arm time was 3-fold control at 0.1 mg/kg and 2-fold control at 1 mg/kg.

Reported findings

Stabinorm at 0.1 mg/kg improved selected rodent endurance and heat-stress measures. Time on the open arm of an elevated plus maze increased threefold at 0.1 mg/kg and twofold at 1 mg/kg.

Elevated plus maze
Open-arm time was 3-fold control at 0.1 mg/kg and 2-fold control at 1 mg/kg.
Endurance and heat stress
The inventors report improvements in endurance, heat tolerance and rotarod time at 0.1 mg/kg, without numerical effects in the narrative.
All reported results, comparisons and limitations →

Formulation. Five extracts from ginseng, Eleutherococcus, leuzea, nettle and St John’s wort. The patent reports laboratory and animal results.

The disclosure tests rodent endpoints and makes a proposed clinical use claim. It supplies no controlled human ME/CFS results.

Publication
RU2390348C1 ↗ · 2010-05-27
Earliest priority / filing
2008-11-14 / 2008-11-14
Original applicant / assignee
ФармацентрВИЛАР
Indexed status
Not shown; official status unverified · checked 2026-11-12
Patent family
42680342 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Средство «Стабинорм» для лечения синдрома хронической усталости

Inventors: Т. В. Лукашина; Т. А. Сокольская; М. Ф. Минеева; В. К. Колхир; Л. В. Крепкова; А. И. Громакова; Е. В. Валь; К. Ю. Калиниченко; Г. М. Тохтабаева; А. В. Рогов.

RU2390348C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2010 · Stabinorm botanical mixture for a claimed fatigue use — RU2390348C1Elevated plus maze: Open-arm time was 3-fold control at 0.1 mg/kg and 2-fold control at 1 mg/kg.
2010Patent / reported experimentsFull text available

Stabinorm botanical mixture for a claimed fatigue use — RU2390348C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Т. В. Лукашина, Т. А. Сокольская, М. Ф. Минеева, В. К. Колхир, Л. В. Крепкова, А. И. Громакова, Е. В. Валь, К. Ю. Калиниченко, Г. М. Тохтабаева, А. В. Рогов · RU2390348C1 · patent family 42680342

Stabinorm at 0.1 mg/kg improved selected rodent endurance and heat-stress measures. Time on the open arm of an elevated plus maze increased threefold at 0.1 mg/kg and twofold at 1 mg/kg.

Results and tables

Reported patent results

Reported findings

Stabinorm at 0.1 mg/kg improved selected rodent endurance and heat-stress measures. Time on the open arm of an elevated plus maze increased threefold at 0.1 mg/kg and twofold at 1 mg/kg.

Rodent groups of 10. The researchers gave the mixture by intragastric administration at 0.1 or 1 mg/kg, usually 30 minutes before testing, and compared with water controls.

Results · Original patent description, claimed composition and animal experiments.
MeasureResultComparison, timing and statistics
Elevated plus mazeOpen-arm time was 3-fold control at 0.1 mg/kg and 2-fold control at 1 mg/kg.
Endurance and heat stressThe inventors report improvements in endurance, heat tolerance and rotarod time at 0.1 mg/kg, without numerical effects in the narrative.

Rodent performance and behavioral endpoints give experimental context for the formulation claim.

Source for these results ↗ · Reviewed 2026-11-12

Population / setting
Rodent groups of 10. The researchers gave the mixture by intragastric administration at 0.1 or 1 mg/kg, usually 30 minutes before testing, and compared with water controls.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The disclosure tests rodent endpoints and makes a proposed clinical use claim. It supplies no controlled human ME/CFS results.
  • Rodent performance and behavioral endpoints give experimental context for the formulation claim.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-12.

Read the source ↗

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗